Background: Resistance to anti-PD-1 remains a considerable clinical challenge for the treatment of patients with classical Hodgkin lymphoma (cHL), and mechanisms of anti-PD-1 resistance remain unknown. This pilot study aims to investigate the tumor microenvironment in patients with cHL relapsing after anti-PD-1. Methods: This study investigated tumor samples of eight patients with cHL, including four patients exposed to anti-PD-1 with a paired longitudinal histological analysis before and after anti-PD-1, and four patients not exposed to anti-PD-1 who served as control for the cellular biological investigations. Fresh cells tumor microenvironment analysis included phenotypic characterization of their T cell surfaces immune checkpoint marker...
Therapeutic blockade of PD-1/PD-L1 shows promising results in Hodgkin’s lymphoma (HL) and in s...
High expression of programmed death receptor 1 (PD-1) and its ligand (PD-L1) by leukocytes in primar...
Classical Hodgkin lymphoma is dominated by the non-neoplastic microenvironment, while the neoplastic...
While classical Hodgkin lymphoma (HL) is highly susceptible to anti-programmed death protein 1 (PD1)...
Classic Hodgkin lymphoma (cHL) is the cancer type most susceptible to anti-programmed-death-receptor...
The etiology of classical Hodgkin lymphoma (cHL) is largely unknown. High serum CD30-levels are asso...
Much focus has been on the interaction of PD-L1 on malignant B-cells with PD-1 on effector T-cells i...
Hodgkin Lymphoma (HL) is a unique disease entity both in its pathology and the young patient populat...
High expression of programmed death receptor 1 (PD-1) and its ligand (PD-L1) by leukocytes in primar...
PD-1/L1 and CTLA-4 blockade immunotherapies have been approved for 13 types of cancers and are being...
Hodgkin lymphoma is characterized by an extensively dominant tumor microenvironment (TME) composed o...
International audienceAbstract The outcome of classical Hodgkin lymphoma (cHL) patients may be relat...
Purpose: There is currently no reliable biomarker to predict who wou ld benefit from anti-PD-1/PD-L1...
Targeted immunotherapy based on PD-1/PD-L1 suppression has revolutionized the treatment of various s...
Therapeutic blockade of PD-1/PD-L1 shows promising results in Hodgkin’s lymphoma (HL) and in s...
High expression of programmed death receptor 1 (PD-1) and its ligand (PD-L1) by leukocytes in primar...
Classical Hodgkin lymphoma is dominated by the non-neoplastic microenvironment, while the neoplastic...
While classical Hodgkin lymphoma (HL) is highly susceptible to anti-programmed death protein 1 (PD1)...
Classic Hodgkin lymphoma (cHL) is the cancer type most susceptible to anti-programmed-death-receptor...
The etiology of classical Hodgkin lymphoma (cHL) is largely unknown. High serum CD30-levels are asso...
Much focus has been on the interaction of PD-L1 on malignant B-cells with PD-1 on effector T-cells i...
Hodgkin Lymphoma (HL) is a unique disease entity both in its pathology and the young patient populat...
High expression of programmed death receptor 1 (PD-1) and its ligand (PD-L1) by leukocytes in primar...
PD-1/L1 and CTLA-4 blockade immunotherapies have been approved for 13 types of cancers and are being...
Hodgkin lymphoma is characterized by an extensively dominant tumor microenvironment (TME) composed o...
International audienceAbstract The outcome of classical Hodgkin lymphoma (cHL) patients may be relat...
Purpose: There is currently no reliable biomarker to predict who wou ld benefit from anti-PD-1/PD-L1...
Targeted immunotherapy based on PD-1/PD-L1 suppression has revolutionized the treatment of various s...
Therapeutic blockade of PD-1/PD-L1 shows promising results in Hodgkin’s lymphoma (HL) and in s...
High expression of programmed death receptor 1 (PD-1) and its ligand (PD-L1) by leukocytes in primar...
Classical Hodgkin lymphoma is dominated by the non-neoplastic microenvironment, while the neoplastic...